RZLT Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -- compared to Rezolute, Inc.'s net margin of -39.02%. Rezolute, Inc.'s return on equity of -63.8% beat Geron Corp.'s return on equity of -29.65%.

Rezolute, Inc. has a consensus price target of $4.25, signalling upside risk potential of 55.68%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 174.81%. Given that Geron Corp. has higher upside potential than Rezolute, Inc., analysts believe Geron Corp. is more attractive than Rezolute, Inc..

Rezolute, Inc. has a beta of 0.390, which suggesting that the stock is 61.035% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Rezolute, Inc.'s net income of -$18.2M is higher than Geron Corp.'s net income of -$18.4M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 4.76x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Rezolute, Inc.'s net margin of 21.32%. Rezolute, Inc.'s return on equity of -63.8% beat Pfizer Inc.'s return on equity of 10.84%.

Rezolute, Inc. has a consensus price target of $4.25, signalling upside risk potential of 55.68%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Rezolute, Inc. has higher upside potential than Pfizer Inc., analysts believe Rezolute, Inc. is more attractive than Pfizer Inc..

Rezolute, Inc. has a beta of 0.390, which suggesting that the stock is 61.035% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Rezolute, Inc.'s net income of -$18.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Rezolute, Inc.'s net margin of -45.06%. Rezolute, Inc.'s return on equity of -63.8% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Rezolute, Inc. has a consensus price target of $4.25, signalling upside risk potential of 55.68%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.74 which suggests that it could fall by -1.85%. Given that Rezolute, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Rezolute, Inc. is more attractive than Sarepta Therapeutics, Inc..

Rezolute, Inc. has a beta of 0.390, which suggesting that the stock is 61.035% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Rezolute, Inc.'s net income of -$18.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 0.90x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -- compared to Rezolute, Inc.'s net margin of 52.48%. Rezolute, Inc.'s return on equity of -63.8% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Rezolute, Inc. has a consensus price target of $4.25, signalling upside risk potential of 55.68%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 144.6%. Given that XOMA Royalty Corp. has higher upside potential than Rezolute, Inc., analysts believe XOMA Royalty Corp. is more attractive than Rezolute, Inc..

Rezolute, Inc. has a beta of 0.390, which suggesting that the stock is 61.035% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.101%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Rezolute, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rezolute, Inc. quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Rezolute, Inc.'s net income of -$18.2M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 35.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 9.17x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.